PTC Therapeutics (PTCT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of PTC Therapeutics (PTCT)
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Key Insights
Critical company metrics and information
Share Price
$51.15Market Cap
$3.94 BillionTotal Outstanding Shares
77.13 Million SharesTotal Employees
995Dividend
No dividendIPO Date
June 20, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.ptcbio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $-177.97 Million |
Net Cash Flow | $353.96 Million |
Net Cash Flow From Investing Activities | $-317.95 Million |
Net Cash Flow From Investing Activities, Continuing | $-317.95 Million |
Net Cash Flow From Financing Activities, Continuing | $849.88 Million |
Net Cash Flow, Continuing | $353.96 Million |
Net Cash Flow From Financing Activities | $849.88 Million |
Net Cash Flow From Operating Activities, Continuing | $-177.97 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss | $-453.20 Million |
Selling, General, and Administrative Expenses | $292.52 Million |
Diluted Earnings Per Share | $-5.94 |
Income/Loss From Continuing Operations After Tax | $-453.20 Million |
Basic Earnings Per Share | $-5.94 |
Income Tax Expense/Benefit | $27.73 Million |
Income Tax Expense/Benefit, Deferred | $4.01 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Attributable To Parent | $-453.20 Million |
Benefits Costs and Expenses | $1.33 Billion |
Revenues | $900.66 Million |
Costs And Expenses | $1.33 Billion |
Diluted Average Shares | $76.94 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Research and Development | $531.06 Million |
Basic Average Shares | $76.94 Million |
Operating Income/Loss | $-134.36 Million |
Income/Loss From Continuing Operations Before Tax | $-425.47 Million |
Other Operating Expenses | $211.44 Million |
Operating Expenses | $1.04 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $-453.20 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $2.90 Billion |
Assets | $1.84 Billion |
Current Liabilities | $610.71 Million |
Liabilities And Equity | $1.84 Billion |
Other Current Assets | $1.05 Billion |
Other Current Liabilities | $551.21 Million |
Intangible Assets | $330.37 Million |
Inventory | $35.67 Million |
Equity | $-1.05 Billion |
Noncurrent Liabilities | $2.29 Billion |
Fixed Assets | $63.17 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $1.28 Billion |
Noncurrent Assets | $560.69 Million |
Wages | $46.21 Million |
Other Non-current Assets | $167.14 Million |
Accounts Payable | $13.29 Million |
Accounts Receivable | $199.98 Million |
Equity Attributable To Parent | $-1.05 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.